WELCOME TO THE 2017 CADTH SYMPOSIUM.

This year’s theme is Measuring Value in Theory and the Real World. As health care spending continues to grow, the need to derive maximum value from every health care dollar becomes increasingly essential. Some aspects of the value equation are widely acknowledged, such as the need to provide equitable access to necessary services, using technologies in an appropriate manner, and to stop paying for technologies that have no evidence of benefit. Overall, however, there is little consensus on value in health care because value means different things to different stakeholders. Depending on one’s perspective, the definition of value might include improved clinical outcomes, faster access to services, affordability, patient preferences, promoting innovation, or a range of other ethical, legal, or social considerations.

During this year’s CADTH Symposium, we’ll discuss value from a theoretical standpoint, and when technologies are used outside of traditional pre-market clinical trials — in the so-called real-world space. Through three plenary sessions, seven breakfast session, 16 workshops, 23 panels, 56 oral presentations, and 80 poster presentations, we hope you will all gain a better understanding of value in theory and in application.

You’ll also have time to talk informally with speakers, colleagues, and friends during the Welcome Reception and Scientific Poster Exhibition on Sunday evening, at A Night at the Museum social event on Monday evening, and at the Awards Luncheon on Tuesday.

There will also be a few nods to Canada’s sesquicentennial.

I hope you find the discussions and networking productive and rewarding.

Dr. Brian O’Rourke
President and CEO, CADTH
On behalf of Members of Ottawa City Council, it is my distinct pleasure to extend a warm welcome to all those participating in the Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, taking place at the Shaw Centre from April 23rd to 25th, 2017.

I am delighted to offer my moral support to CADTH for providing a valuable forum for health technology assessment stakeholders and decision-makers responsible for the optimal use of drugs and health technologies from across Canada, and beyond its borders, to convene under the theme "Measuring Value in Theory and the Real World". Delegates will benefit from networking, sharing evidence, and learning more about value in healthcare through their participation in workshops and sessions moderated by leading experts in the field.

As Head of Council, I want also to acknowledge CADTH, guest speakers, and sponsors for dedicating efforts, expertise and resources to the successful organization of this educational meeting of international scope.

As Mayor of the host city, I invite visitors to explore the Ottawa Sports Hall of Fame and the Barbara Ann Scott Gallery at City Hall, as well as the revitalized Lansdowne park, its heritage pavilions, and new TD Place, home of the Ottawa REDBLACKS CFL team, and Ottawa Fury FC United Soccer League team.

Canada celebrates its 150th birthday in 2017 and the grandest festivities will be unfolding in Ottawa. I hope that you will join us in our nation's capital for the sesquicentennial anniversary.

Allow me to convey my best wishes to the participants for a very productive and rewarding experience, as well as to the visitors for a most enjoyable stay in Ottawa.

Sincerely,

Jim Watson
Mayor/Maire

---

J'ai l'immense plaisir de souhaiter la bienvenue, au nom des membres du Conseil municipal d'Ottawa, à tous les participants au Symposium de l'Agence canadienne des médicaments et des technologies de la santé (ACMTS), qui a lieu du 23 au 25 avril 2017 au Centre Shaw.

Je suis ravi d'apporter mon soutien moral à l'ACMTS qui offre aux intervenants et aux décideurs en matière d'évaluation de la technologie de la santé, responsables de l'usage optimal de médicaments et de technologies de la santé, un cadre précieux où se réunir sur le thème Évaluer selon la théorie et la réalité. Les délégués, venus de partout au Canada et de l'étranger, pourront profiter d'occasions de réseautage, de partage de preuves et d'apprentissage sur l'enjeu de la valeur des soins de santé en participant à des ateliers et à des séances animés par des spécialistes éminents du domaine.

En tant que chef du Conseil, je tiens également à remercier l'ACMTS, les conférenciers et les commanditaires pour les efforts, le savoir-faire et les ressources qu'ils ont consacrés à l'organisation réussie de cette réunion à caractère éducatif d'envergure internationale.

En tant que maire de la ville hôte, j'invite les visiteurs à explorer le Temple de la renommée des sports d'Ottawa et la Galerie Barbara-Ann-Scott, tous deux situés à l'hôtel de ville, ainsi que le parc Lansdowne, qui a récemment fait peau neuve, ses édifices patrimoniaux, de même que la nouvelle Place TD, domicile du ROUGE et NOIR d'Ottawa, équipe de la Ligue canadienne de football, et du Fury FC d'Ottawa, équipe de la United Soccer League.

Le Canada célèbre son 150e anniversaire en 2017 et des festivités grandioses auront lieu à Ottawa. J'espère que vous vous joindrez à nous à cette occasion.

Je souhaite aux participants une rencontre très productive et enrichissante et aux visiteurs, un séjour des plus agréables à Ottawa.

Meilleures salutations.

Jim Watson, Mayor/Maire
THANK YOU
We gratefully acknowledge the contribution of our sponsors to the success of the 2017 CADTH Symposium. This event could not continue to grow and improve without you!

PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

MEDIA SPONSOR

We would also like to acknowledge the support of our funders. CADTH’s activities, programs, and services, including the CADTH Symposium, are made possible through financial contributions from Health Canada and the government of: Alberta, British Columbia, Prince Edward Island, Manitoba, New Brunswick, Nova Scotia, Nunavut, Ontario, Saskatchewan, Newfoundland and Labrador, Northwest Territories, Yukon.
# MINI SCHEDULE

## SUNDAY, APRIL 23, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 – 1900</td>
<td>Registration Desk Open</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Morning Workshop Registration</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0900 – 1200</td>
<td>Workshops AM</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1200 – 1300</td>
<td>Afternoon Workshop Registration</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>1300 – 1600</td>
<td>Workshops PM</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1700 – 1900</td>
<td>Welcome Reception and Scientific Poster Exhibition</td>
<td>LVL 4 Trillium Ballroom</td>
</tr>
</tbody>
</table>

## MONDAY, APRIL 24, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730 – 1700</td>
<td>Registration Desk Open</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Breakfast</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>0900 – 0930</td>
<td>Official Opening</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>0930 – 1045</td>
<td>Opening Plenary</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>1045 – 1115</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1115 – 1230</td>
<td>Concurrent Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1230 – 1300</td>
<td>Lunch</td>
<td>LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1300 – 1445</td>
<td>Concurrent Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1445 – 1515</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1515 – 1630</td>
<td>Concurrent Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1800 – 2200</td>
<td>Social Event: A Night at the Museum</td>
<td>Canadian Museum of History Grand Hall</td>
</tr>
</tbody>
</table>

## TUESDAY, APRIL 25, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 1700</td>
<td>Registration Desk Open</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0700 – 0800</td>
<td>Breakfast</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>0730 – 0830</td>
<td>Breakfast Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>0845 – 1000</td>
<td>Plenary Session 2</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>1000 – 1030</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1030 – 1145</td>
<td>Concurrent Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1145 – 1315</td>
<td>Awards Luncheon</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>1315 – 1430</td>
<td>Concurrent Sessions</td>
<td>2nd Floor</td>
</tr>
<tr>
<td>1430 – 1500</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1500 – 1615</td>
<td>Closing Plenary</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>1615 – 1630</td>
<td>Official Closing</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
</tbody>
</table>
SPECIAL EVENTS

WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION

Sunday, April 23  
1700 — 1900  
Trillium Ballroom, Level 4  

The Welcome Reception features scientific posters and the opportunity to meet and talk with the authors about their work. Dr. Brian O’Rourke, President and CEO of CADTH, Dr. Terrence Sullivan, Chair of CADTH’s Board of Directors, and Mr. Michael Crockatt, President and CEO of Ottawa Tourism, will welcome attendees. A cash bar and light snacks will be available.

OFFICIAL OPENING

Monday, April 24  
0900 — 0930  
Canada Hall 1, Level 3  

Dr. Brian O’Rourke, President and CEO of CADTH, will welcome Symposium participants and describe some of the Symposium highlights.

A NIGHT AT THE MUSEUM – EVENING SOCIAL EVENT

Monday, April 24  
1800 – 2200 (buses will be leaving the Shaw Centre at 18:00)  
Canadian Museum of History  

In keeping with Canada’s 150th Anniversary, the Canadian Museum of History is the centrepiece for this evening of discovery, Canadian-inspired food, and upbeat entertainment. Special guest speaker Dr. Danielle Martin will share some of her ideas from her new book Better Now: Six Big Ideas to Improve Health Care for All Canadians.

CADTH RECOGNITION AWARD LUNCHEON

Tuesday, April 25  
1145 — 1315  
Canada Hall 1, Level 3  

Join us in honouring the 2017 recipients of the Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment and the Dr. Maurice McGregor Award. The winners of our poster competition will also receive their awards at the luncheon. As this is a plated lunch, please arrive promptly.
OPENING PLENARY

Monday, April 24
0930 — 1045
Canada Hall 1, Level 3

Measuring Value in Theory and the Real World
As health care spending continues to grow year after year, the need to derive maximum value from every health care dollar becomes increasingly essential. Some aspects of the value equation are widely acknowledged, such as the need to provide equitable access to necessary services, to use technologies in an appropriate manner, and to stop paying for high-cost technologies that have no evidence of benefit. Overall, however, there is little consensus on value in health care because the meaning of value is different for different stakeholders, and there is a lack of clarity about goals. Depending on one’s perspective, the definition of value might include improved clinical outcomes, access to services, cost, safety, patient preferences, convenience, promoting innovation, or a range of other ethical, technical, or system-level considerations. The opening plenary will explore how different health system stakeholders perceive value: what it means to them, what they value and why, and how they measure value in theory and in the real world.

SPEAKERS:
Christopher McCabe, PhD
Bettina Ryll, MD, PhD
Tom Maston CPA, CA, CHE
Dianne Carmichael
Ken Milne, MD, MSc, CCFP(EM), FCFP, FRRMS

PLENARY 2

Tuesday, April 25
0845 — 1000
Canada Hall 1, Level 3

Meaningful Stakeholder Engagement
The consumerization of health care — marked by patients taking an increasingly active role in their own care and health systems reorienting the delivery of services around the end-user — is changing the way payers, health care providers, and industry engage with patients and with each other. An expert panel will explore these changing relationships, look at how and when different stakeholders want to be engaged (and by whom), and discuss how effective engagement can help achieve high value for the health care system.

SPEAKERS:
Dr. Stuart Peacock
MJ DeCoteau
Pamela Fralick
Dr. Marcia Anderson
Janet Knox
CLOSING PLENARY

Tuesday, April 25
1500 — 1615
Canada Hall 1, Level 3

Aligning Regulation and Reimbursement

Regulatory approval and reimbursement approval are both necessary to bring health technologies to market. Because the assessment processes for regulation and reimbursement are separate and typically sequential, the total time from the development of a new product to when it is funded as part of the public health system can take longer than anyone would like. An expert panel will look at the issues, challenges, and opportunities associated with aligning regulatory and reimbursement processes for health technologies more closely so that value is measured and considered much earlier in the overall process. What are the implications for different stakeholders? What work has been done to date? What are the next steps?

SPEAKERS: Brent Fraser
Dr. Hans-Georg Eichler
Michele Evans
John Helou
Robyn Lim, PhD
Now, with the strength of Quintiles and IMS Health united in one organization, the future of real-world evidence has never been more promising.

QuintilesIMS Real-world Insights support Outcomes Research and Health Technology Assessments to help clients in Canada drive healthcare forward.

- **Study design expertise** – Providing insight into the burden of illness, disease incidence and prevalence, comparative effectiveness, late phase research and registries
- **Innovation in data generation** – Using EMR data to drive retrospective and prospective studies
- **Linking patient insights** – The ability to build a holistic view of the patient from multiple data sources within the health system

Our Health Access & Outcomes team is a fast expanding group of data scientists, epidemiologists, strategists, statisticians, outcomes study specialists, and health economists.

Want to learn more about career opportunities at QuintilesIMS? Meet with one of our team at the 2017 CADTH Symposium or visit [www.quintilesims.com/careers](http://www.quintilesims.com/careers)
SPEAKERS
OPENING PLENARY

CHRISTOPHER MCCABE  PHD
University of Alberta

Professor Christopher McCabe is a health economist and the Capital Health Chair in Emergency Medicine Research at the University of Alberta. He is also the Principal Investigator on PACEOMICS and the Precision Medicine Policy Network. His primary research interest is in the development of efficient research and development processes for biotherapies and devices in the context of value-based reimbursement market-access hurdles. He has published more than 100 peer-reviewed papers, book chapters, and monographs. He has acted as a consultant for public- and private-sector organizations in Europe, North America, and Australasia, most notably, with the National Institute for Health and Care Excellence (NICE) in the UK, where he held various roles between 2003 and 2011. Professor McCabe was a member of the Health Economics Working Group responsible for the recent update of CADTH’s Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition).

BETTINA RYLL  MD, PHD
Founder, Melanoma Patient Network Europe

Dr. Bettina Ryll holds a medical degree from the Free University of Berlin, Germany and a PhD in Biomedical Sciences from University College London in London, UK.

After losing her husband to melanoma, Dr. Ryll founded the Melanoma Patient Network Europe. She developed a special interest in patient-centric clinical research, in particular, innovative trial designs and novel drug-development concepts, such as MAPPS (medicines’ adaptive pathways to patients), previously known as adaptive licensing. Lately, her focus has moved to sustainable health care models that ensure access to innovative therapies for cancer patients and incentives for sustainable innovation.

Dr. Ryll is involved in numerous initiatives promoting evidence-based advocacy. She is fascinated by the enormous potential and capacity of patient networks to educate and support patients and capture data at the primary data source — the patients themselves — to generate evidence at a granularity level that is inaccessible to outsiders.
Since 2015, Dr. Ryll has chaired the European Society for Medical Oncology (ESMO) Patient Advocates Working Group (PAWG), the first time this position has been held by a non-oncologist. The PAWG is responsible for the advocacy track at the annual ESMO meetings. It organizes workshops of interest to the wider advocacy and medical communities and has an advisory function for ESMO activities.

TOM MASTON  CPA, CA, CHE
Deputy Minister of Health, Government of New Brunswick

Tom Maston was appointed Deputy Minister of the Government of New Brunswick’s Department of Health in February 2014. Previously, he was the Assistant Deputy Minister of the department’s Corporate Services Branch. He has 17 years of experience as a Vice-President with New Brunswick’s regional health authorities.

Mr. Matson is a chartered accountant and has several years of experience in the private sector. He is also a Certified Health Executive through the Canadian College of Health Leaders.

DIANNE CARMICHAEL
President and CEO, Carmichael Worldwide Inc./Council of Canadian Innovators

Dianne Carmichael is an entrepreneurial leader with a track record of success in social impact and business spanning multiple industries over 25 years. As Chief Advisor for the Health Technology Division of the Council of Canadian Innovators — created by RIM co-founder Jim Balsillie — Ms. Carmichael brings the voices of the CEOs of scaling Canadian technology companies to government and policy-makers.

Currently, she is co-founding a digital health technology platform to connect health care stakeholders. The platform is predicated on patient consent using blockchain and embedded artificial intelligence technologies to measure risk stratification and personalized patient outcomes through genomics and pharmacogenetics.

Previously, Ms. Carmichael led Best Doctors, a remote health care second-opinion, navigation, and advocacy company focused on employee benefit plans that grew to over six million Canadian users and 40 million patient users worldwide. She is the Founder and President of UHN Solutions, and served as Managing Director of MaRS Health and Innovation, where she helped health technology companies expand and scale globally. Previously, Ms. Carmichael was Chair and CEO of Worldsource Wealth Management, building the company to more than $8 billion in assets. She has founded and gone on to sell a high-net-worth portfolio company, a skin care company, and recently built the foundation for a Canadian digital health technology company.
Ms. Carmichael serves on the boards of the Holland Bloorview Kids Rehabilitation Hospital, Patients Canada, the Canadian Association for Person-Centred Health, the Dean’s Health Advisory Board at York University, the Centre for Commercialization of Regenerative Medicine (CCRM), and Closing the Gap Healthcare. Recognized as one of Canada’s Most Powerful Women by the Women’s Executive Network, She is also among Canada’s Top 20 Business Women, Top Women to Watch, Canadian Women Transforming Healthcare, and Schulich’s Top 100 Canadian Business Leaders.

She is a graduate of the University of Waterloo.

KEN MILNE  MD, MSC, CCFP-EM, FCFP, FRRMS
Chief of Staff, South Huron Hospital Association and creator of the knowledge translation project, The Skeptics’ Guide to Emergency Medicine

Dr. Ken Milne is the Chief of Staff at South Huron Hospital Association in Exeter, Ontario, Canada. He has been doing research for over 30 years and has published on a variety of topics. He is passionate about skepticism and critical thinking. He is the creator of the knowledge translation project, The Skeptics’ Guide to Emergency Medicine. When not working clinically or doing research, he is trying hard to be an endurance athlete. Dr. Milne is married and has three amazing children.

PLENARY 2

DR. STUART PEACOCK
Co-Director, Canadian Centre for Applied Research in Cancer Control

Dr. Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship in the Faculty of Health Sciences at Simon Fraser University. He is Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC) and Head of Cancer Control Research at the BC Cancer Agency. Previously, he held positions at Monash University in Australia and the University of York in the UK.

Over the past 20 years, Dr. Peacock’s main interests have focused on research into developing more effective cancer systems, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors. He has also acted as a consultant on priority-setting methods for the World Health Organization and for governments in North and South America, Europe, Asia, and Australia.
MJ DECOTEAU
Founder and Executive Director, Rethink Breast Cancer

MJ DeCoteau is Founder and Executive Director of Rethink Breast Cancer, the young women’s breast cancer movement. Rethink seeks to bring relevant awareness to the 40s-and-under crowd, foster a new generation of young and influential breast cancer supporters, and respond to the unique needs of young women going through breast cancer.

At 22, after losing her mother to a four-year battle with breast cancer, Ms. DeCoteau was hard-pressed to find relevant information about her own risk factors that was not scary and overwhelming. She quickly realized that young people were in the dark about breast cancer simply because they weren’t being targeted by awareness campaigns and other efforts. By 2001, she had brought together a group of Canada’s most innovative, energetic, and creative minds to found Rethink Breast Cancer, putting young people concerned about and affected by the disease into the spotlight for the very first time.

In its first year, the charity secured exclusive Canadian rights to the world-famous Fashion Targets Breast Cancer campaign. By 2004, Ms. DeCoteau was featured in Maclean’s magazine’s Honour Roll as one of the Top 10 Canadians Who Make a Difference.

Today, Ms. DeCoteau remains responsible for the overall direction, management, strategy, and creative vision of a growing Rethink Breast Cancer. Rethink’s small but dynamic team of dedicated staff and volunteers has continued to pave the way for the young women’s breast cancer movement, creating groundbreaking new resources, campaigns, events, research, and advocacy initiatives to bring much-needed support and attention to the cause.

PAMELA FRALICK
President, Innovative Medicines Canada

Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, she leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them.
**DR. MARCIA ANDERSON**  
*Medical Officer of Health, Winnipeg Regional Health Authority*

Dr. Marcia Anderson is Cree-Saulteaux, with roots going to the Norway House Cree Nation and Peguis First Nation in Manitoba. She practices both internal medicine and public health as a Medical Officer of Health with the Winnipeg Regional Health Authority. In September 2011, she took the position of Head of the Section of First Nations, Métis, and Inuit Health in the Department of Community Health Sciences at the University of Manitoba. She was recognized for her contributions to the health of Indigenous peoples with a National Aboriginal Achievement award in March 2011.

---

**JANET KNOX**  
*President and CEO, Nova Scotia Health Authority*

As President and CEO of Nova Scotia Health Authority, Ms. Knox is focused on creating a healthier Nova Scotia. She believes in working collaboratively with Nova Scotians and key partners to improve care and services, and positively shape the future of health and the health system in that province. She brings more than four decades of health system experience to this role, from Nova Scotia, Canada and beyond. She started her career as a registered nurse and has extensive experience in clinical care, education, research, and health care administration, including 10 years as President and CEO of Annapolis Valley Health. She holds a bachelor of nursing from the University of New Brunswick, a master’s degree in nursing from Dalhousie University, and a master of business administration from Saint Mary's University. She is also a Certified Health Executive with the Canadian College of Health Leaders. A strong supporter of community and economic development, Ms. Knox currently serves on the Board of Directors for 211 Nova Scotia and HealthcareCAN. As a member of the CEO Health and Safety Leadership Charter she is also committed to working with other leaders to make Nova Scotia the safest place to live and work in Canada.
CLOSING PLENARY

BRENT FRASER
Vice-President, Pharmaceutical Reviews, CADTH

Brent Fraser is the Vice-President, Pharmaceutical Reviews for CADTH, with responsibility for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, therapeutic class reviews, and optimal use projects, as well as drug-related Environmental Scans, Horizon Scans, and Rapid Response. Mr. Fraser and his team deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies. Mr. Fraser is known as a thoughtful, listening, and collaborative leader who translates evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with strategic skills developed over many years working in the field of drug-funding decisions. Mr. Fraser holds a master of business administration from York University and a bachelor of science in pharmacy from the University of Toronto. He is a member of the Ontario College of Pharmacists.

HANS-GEORG EICHLER  MD, MSc
Senior Medical Officer, European Medicines Agency

Dr. Hans-Georg Eichler is the Senior Medical Officer at the European Medicines Agency in London, UK, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr. Eichler was at the Medical University of Vienna in Austria for 15 years. His positions there included Vice-Rector for Research and International Relations since 2003, and Professor and Chair of the Department of Clinical Pharmacology since 1992. His other previous positions included President of the Vienna School of Clinical Research and Co-Chair of the Austrian Social Security Association’s Committee on Reimbursement of Drugs. His industry experience includes time spent at Ciba-Geigy Research Labs in the UK, and doing outcomes research at Merck & Co., in New Jersey. Dr. Eichler graduated with a medical degree from the Vienna University Medical School and a master of science degree in toxicology from the University of Surrey in Guildford, UK. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.
MICHELE EVANS
Assistant Deputy Minister, Pharmaceutical & Supplementary Benefits Division, Government of Alberta

A pharmacist who worked for a number of years in the private sector — both in small community pharmacies and with large international pharmaceutical companies — Michele Evans is passionate about the Alberta public service and believes strongly in working collaboratively and making connections with people. Her career with the Alberta government includes experience with the Ministry of Health, Treasury Board and Enterprise, and Enterprise and Advanced Education in the area of economic development policy. Actively involved in volunteer opportunities in her community, she is a mentor for emerging leaders and serves on the Board of the Bessie Nichols School Fundraising Society.

JOHN HELOU
President and Canada Lead, Internal Medicine, Pfizer Canada

John Helou has been actively involved in several industry, business, and community associations. He is currently a member of the board of directors of Innovative Medicines Canada, a member of the Business Council of Canada, and a member of the Dean’s Advisory Board and the Campaign Cabinet at the University of Toronto, Faculty of Pharmacy. Formerly, he was Chair of the board of directors for Innovative Medicines Canada, Vice-Chair of the board of directors of BIOTECanada, and a board member of the Advanced Coronary Treatment (ACT) Foundation.

In 2014, Mr. Helou was inducted into the Canadian Healthcare Marketing Hall of Fame.
ROBYN LIM  PHD
Senior Science Advisor, Health Products and Food Branch, Health Canada

Dr. Robyn Lim has been helping to remodel Canada’s federal drug regulatory system since 2006. She developed the benefit–harm–uncertainty concept for the Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law), and continues to support the Health Products and Food Branch’s (HPFB) modernization efforts toward optimized patient outcomes. Previously, she was a reviewer for 10 years with the Therapeutic Products Directorate’s Central Nervous System Division. While there, she developed the Directorate’s Good Review Guiding Principles. She has received HPFB awards for Excellence in Risk Management and Creativity and Innovation. Since 2007, she has participated in international regulatory science initiatives on structured benefit-risk and uncertainty management, and is a member of the Massachusetts Institute of Technology’s NEW Drug Development ParadigmS (MIT NEWDIGS) adaptive biomedical innovation community and Data Program sub-teams. Dr. Lim also works with Canadian patients, creating with them a patient’s treatment benefit–harm–uncertainty decision guide.

Dr. Lim has bachelor of science (honours) and master’s degrees from the Biochemistry Department, Queen's University, Kingston, Ontario, and a doctorate in Molecular Neurophysiology from the Physiological Laboratory, University of Cambridge and Trinity College, Cambridge, UK.
Patented Payer Experience

Market Research

Payer Engagement

Analytic Tools
## SCHEDULE

### SUNDAY, APRIL 23, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 – 1900</td>
<td>Registration Desk Open</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Morning Workshop Registration</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0900 – 1200</td>
<td><strong>Workshop AM-1</strong>&lt;br&gt;<strong>An Introduction to Health Technology Assessment</strong>&lt;br&gt;Introductory. Will be of particular interest to patients, students, and people new to health technology assessment (HTA).&lt;br&gt;• Thanh Nguyen, MD, MPH, PhD, Institute of Health Economics&lt;br&gt;• Nancy Sikich, MSc, Health Quality Ontario&lt;br&gt;• Laura Weeks, PhD, CADTH</td>
<td>Room 210</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop AM-2</strong>&lt;br&gt;<strong>Incorporating Heterogeneity Into Economic Evaluation: A Workshop Based on the Revised (Fourth Edition) CADTH Guidelines for Economic Evaluation</strong>&lt;br&gt;Advanced. Will be of particular interest to health economists.&lt;br&gt;• Dr. Doug Coyle, University of Ottawa&lt;br&gt;• Karen Lee, CADTH</td>
<td>Room 211</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop AM-3</strong>&lt;br&gt;<strong>How Can Policy-Makers and Clinicians Trust the Results of a Network Meta-Analysis? A Workshop on How to Apply the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Tool</strong>&lt;br&gt;Introductory. Will be of particular interest to policy-makers and clinicians.&lt;br&gt;• Dr. Andrea Tricco, Li Ka Shing Knowledge Institute, St. Michael's Hospital&lt;br&gt;• Dr. Areti Angeliki Veroniki, Li Ka Shing Knowledge Institute, St. Michael's Hospital</td>
<td>Room 201</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop AM-4</strong>&lt;br&gt;<strong>How Should We Argue About Ethics and Value? Applied Philosophy for Health Technology Assessment</strong>&lt;br&gt;Intermediate. Will be of particular interest to HTA producers.&lt;br&gt;• Ken Bond, CADTH&lt;br&gt;• Matthew Barker, Concordia University&lt;br&gt;• Katherine Duthie, Alberta Health Services</td>
<td>Room 209</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop AM-5</strong>&lt;br&gt;<strong>Decision Modelling Using R</strong>&lt;br&gt;Intermediate. Will be of particular interest to health economists, decision modellers, and researchers.&lt;br&gt;• Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute</td>
<td>Room 212</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop AM-6</strong>&lt;br&gt;<strong>Using the OncoSim Family of Microsimulation Models to Evaluate Cancer Control Strategies</strong>&lt;br&gt;Intermediate. Will be of particular interest to policy-makers, health economists, researchers, and clinicians.&lt;br&gt;• William Flanagan, Principal Researcher, Statistics Canada&lt;br&gt;• Dr. Keiko Asakawa, Researcher, Statistics Canada&lt;br&gt;• Prof. Michael Wolfson, University of Ottawa&lt;br&gt;• Dr. Bill Evans, McMaster University&lt;br&gt;• Natalie Fitzgerald, Canadian Partnership Against Cancer&lt;br&gt;• Saima Memon, Canadian Partnership Against Cancer&lt;br&gt;• Dr. Cindy Gauvreau, Canadian Partnership Against Cancer</td>
<td>Room 204</td>
</tr>
</tbody>
</table>
### SUNDAY, APRIL 23, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop AM-7</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900 – 1200</td>
<td>Measuring and Valuing Patient Preferences in Randomized Clinical Trials</td>
<td>Room 202</td>
</tr>
<tr>
<td></td>
<td>Introductory. Will be of particular interest to HTA producers and health care professionals.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Feng Xie, McMaster University</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop AM-8</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clearer Communication and Plain Language Writing: Making Health Research Make Sense</td>
<td>Room 203</td>
</tr>
<tr>
<td></td>
<td>Intermediate. Will be of interest to all audiences.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Janice Mann, CADTH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-1</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1200 – 1300</td>
<td>Making Tough Decisions: An Interactive Deliberative Exercise</td>
<td>Room 201</td>
</tr>
<tr>
<td></td>
<td>Introductory. Will be of particular interest to patients, students, and people new to HTA.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sarah Berglas, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ken Bond, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Frank Gavin, CDEC Public Member</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mirhad Loncar, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Valerie McDonald, pERC Patient Member</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Brad Mitchelmore, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jo Nanson, pERC Patient Member</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tamara Rader, CADTH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-2</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300 – 1600</td>
<td>Quantifying and Presenting Uncertainty: A Workshop Based on the Revised (Fourth Edition) CADTH Guidelines for Economic Evaluation</td>
<td>Room 211</td>
</tr>
<tr>
<td></td>
<td>Advanced. Will be of particular interest to health economists.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Christopher McCabe, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mike Paulden, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Karen Lee, CADTH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-3</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The State of Affairs in Health Technology Reassessment: An Interactive Workshop</td>
<td>Room 203</td>
</tr>
<tr>
<td></td>
<td>Introductory. Will be of particular interest to health care system decision-makers, producers, and health care professionals.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lesley Sonil, University of Calgary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Fiona Clement, University of Calgary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Stirling Bryan, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Tammy Clifford, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Marc Pelletier, Institute for Health System Transformation &amp; Sustainability</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-4</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>From Lingo to Application: Use of Confounder Summary Scores (Propensity Scores and Disease Risk Scores) in Health Technology Assessment</td>
<td>Room 212</td>
</tr>
<tr>
<td></td>
<td>Introductory. Will be of particular interest to HTA producers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Jason Guertin, McMaster University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Mina Tadrous, Ontario Drug Policy Research Network</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Workshop PM-5</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>1300 – 1600</td>
<td>Early Health Technology Assessment Case Study of Pre-Market Evaluation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intermediate. Will be of particular interest to HTA producers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Murray Krahn, Toronto Health Economics and Technology Assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(THETA) Collaborative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Valeria Rac, Toronto Health Economics and Technology Assessment (THETA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collaborative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Lusine Abrahamyan, Toronto Health Economics and Technology Assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(THETA) Collaborative</td>
<td></td>
</tr>
<tr>
<td>Room 209</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Getting to Know the pan-Canadian Pharmaceutical Alliance</td>
</tr>
<tr>
<td></td>
<td>Intermediate. Will be of interest to all audiences.</td>
</tr>
<tr>
<td></td>
<td>• Imran Ali, pan-Canadian Pharmaceutical Alliance</td>
</tr>
<tr>
<td></td>
<td>• Sang Mi Lee, pan-Canadian Pharmaceutical Alliance</td>
</tr>
<tr>
<td>Room 210</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Economic Evaluation Using Person-Level Data: Bridging Theory to Practice</td>
</tr>
<tr>
<td></td>
<td>Intermediate. Will be of particular interest to HTA producers, researchers,</td>
</tr>
<tr>
<td></td>
<td>and health care professionals.</td>
</tr>
<tr>
<td></td>
<td>• Dr. Wanrudee Isaranuwatchai, St. Michael's Hospital</td>
</tr>
<tr>
<td></td>
<td>• Dr. Kednapa Thavorn, The Ottawa Hospital Research Institute</td>
</tr>
<tr>
<td>Room 204</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop PM-8</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700 – 1900</td>
<td>Making Rational Drug Therapy Decisions at the Point of Care</td>
</tr>
<tr>
<td></td>
<td>Introductory. Will be of interest to all audiences.</td>
</tr>
<tr>
<td></td>
<td>• Brent Jensen, RxFiles Academic Detailing</td>
</tr>
<tr>
<td></td>
<td>• Dr. Roland Halil, University of Ottawa</td>
</tr>
<tr>
<td></td>
<td>• Dr. Jay Mercer, Family Physician</td>
</tr>
<tr>
<td>Room 202</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Welcome Reception and Scientific Poster Exhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Dr. Brian O'Rourke, President and CEO, CADTH</td>
</tr>
<tr>
<td></td>
<td>• Dr. Terrence Sullivan, Chair, CADTH Board of Directors</td>
</tr>
<tr>
<td>LVL 4 Trillium Ballroom</td>
<td></td>
</tr>
</tbody>
</table>
MAKE A DIFFERENCE IN HEALTH CARE.

CADTH is inviting nominations for its Board of Directors and Committees.

We’re seeking 21 new members of our Board of Directors and advisory and expert committees — that includes experts, patients, and members of the public.

Find out more: cadth.ca/nominations

XIV

HTAi 2017
Rome, Italy

JUNE 17-21, 2017

Towards An HTA Ecosystem: From Local Needs To Global Opportunities

HTAi2017.org
### Monday, April 24, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730 – 1700</td>
<td>Registration Desk Open</td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Breakfast</td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td>0900 – 0930</td>
<td><strong>Official Opening</strong></td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td></td>
<td>• Dr. Brian O’Rourke, CADTH</td>
<td></td>
</tr>
<tr>
<td>0930 – 1045</td>
<td><strong>Opening Plenary</strong></td>
<td>LVL 3 Canada Hall 1</td>
</tr>
<tr>
<td></td>
<td>Measuring Value in Theory and the Real World</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Opening Plenary will explore how different stakeholders define and measure value: what it means to them, what they value and why, and how they measure value both in theory and in the real world.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Professor Christopher McCabe PhD, Capital Health Chair in Emergency Medicine Research, Adjunct Professor, Department of Economics, and Adjunct Professor, School of Public Health, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bettina Ryll, MD, PhD, Founder, Melanoma Patient Network Europe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tom Maston, Deputy Minister of Health, Province of New Brunswick</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dianne Carmichael, President and CEO, Carmichael Worldwide Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ken Milne, MD, MSc, CCFP(EM), FCFP, FRRMS, Chief of Staff, South Huron Hospital Association. Creator of the knowledge translation project The Skeptics’ Guide to Emergency Medicine.</td>
<td></td>
</tr>
<tr>
<td>1045 – 1115</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1115 – 1230</td>
<td><strong>Concurrent Session A1 — Panel Discussion</strong></td>
<td>Room 210</td>
</tr>
<tr>
<td></td>
<td>The Value of Drug Policy to Decrease the Costs and Consequences of Inappropriate Prescribing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Justin Turner, Institut universitaire de gériatrie de Montréal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Jay Shaw, Women’s College Hospital Institute for Health System Solutions and Virtual Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. James Silvius, Alberta Health Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Marnie Mitchell, Health Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session A2 — Panel Discussion</strong></td>
<td>Room 201</td>
</tr>
<tr>
<td></td>
<td>Medical Devices: Generating and Using Real-World Observational Data for Decision-Making on Value</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Tammy Clifford, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Jessica Jalbert, LA-SER Group and Weill Cornell Medical College</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Laura Hatfield, Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Patricia Trbovich, University Health Network and University of Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mark Campbell, National Institute for Health and Care Excellence (NICE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session A3 — Panel Discussion</strong></td>
<td>Room 209</td>
</tr>
<tr>
<td></td>
<td>PRISM: Informing Canadian Rare Disease Drug Policy Through Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Devidas Menon, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Tania Stafinski, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Aidan Hollis, University of Calgary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Durhane Wong-Rieger, Canadian Organization for Rare Disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chad Mitchell, Alberta Health Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• David Lee, Health Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Judith Glennie, Promoting Rare Disease Innovations Through Sustainable Mechanisms (PRISM)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session A4 — Panel Discussion</strong></td>
<td>Room 203</td>
</tr>
<tr>
<td></td>
<td>Where Is the Value in Broadening the Evaluative Space of Outcome Measurement in Health Technology Assessment?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. David Whitehurst, Simon Fraser University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Jeffrey Hoch, University of California</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Fiona Clement, University of Calgary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Logan Trenaman, University of British Columbia</td>
<td></td>
</tr>
</tbody>
</table>
### MONDAY, APRIL 24, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session A5 — Panel Discussion</th>
<th>Room 204</th>
</tr>
</thead>
<tbody>
<tr>
<td>1115 – 1230</td>
<td>The Future of Scientific Advice in Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Simon Yunger, Hoffmann-La Roche Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Amy Sood, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Jens Grueger, Roche Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Cathy Parker, Health Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Don Husereau, Institute of Health Economics</td>
<td></td>
</tr>
</tbody>
</table>

### Concurrent Session A6 — Panel Discussion

Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?

- Barry Stein, Colorectal Cancer Association of Canada
- Matthew Brougham, Brougham Consulting and Laser Analytica
- Alexandra Chambers, CADTH
- Kathy Gesy, Saskatchewan Cancer Agency
- Dr. Reiner Banken, Reiner Banken Consulting
- Elizabeth Cobbs, Merck

### Concurrent Session A7 — Panel Discussion

The Role of Artificial Intelligence in Canada’s Health Care Sector

- Dianne Carmichael, Carmichael Worldwide / Council of Canadian Innovators
- Marc Fiume, DNAstack
- Graeme Moffat, InteraXon
- Mike Monteith, ThoughtWire

### Concurrent Session A8 — Panel Discussion

Precision Medicine: Applying Theory to Practice for Value With Companion Diagnostics (CDx)

- Dr. Don Juzwishin, Alberta Health Services
- Prof. Christopher McCabe, University of Alberta
- Dr. Tania Bubela, University of Alberta
- Dr. Judith Hugh, University of Alberta and Alberta Health Services

### 1230 – 1330

**Lunch**

LVL 3 Parliament Foyer 1

### 1330 – 1445

**Concurrent Session B1 — Oral Presentations**

**PATIENT AND PUBLIC ENGAGEMENT**

- Public and Patient Engagement in Canadian Drug Assessment: 10 Years of Experience in Ontario and at the CADTH Common Drug Review
  - Prof. Katherine Boothe, McMaster University
- Patient and Public Engagement in Health Technology Assessment: An Update of a Systematic Review of International Experiences
  - Prof. Marie-Pierre Gagnon, Université Laval
- Bringing the Voice of Patients Into Health Technology Assessment at Health Quality Ontario
  - Mark Weir, Health Quality Ontario
### MONDAY, APRIL 24, 2017

**1330 – 1445**

**Concurrent Session B2 — Oral Presentations**

**Room 204**

**APPROPRIATE USE**

- Reaching and Engaging the Elderly in Deprescribing
  - Janet Currie, Canadian Deprescribing Network

- Economic Evaluation of Disinvestment in Hydroxyethyl Starches for Coronary Artery Bypass Surgery
  - Dr. Ava John-Baptiste, Western University

- Evidence Uninformed: Venous Thromboembolism Prophylaxis for Medical Patients as a Required Organizational Practice
  - Dr. Aaron Tejani, University of British Columbia

**Concurrent Session B3 — Oral Presentations**

**Room 209**

**MEDICAL IMAGING: DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY**

- Proton Beam Therapy: Making Decisions on Out-of-Country Referrals
  - Andra Morrison, CADTH

- Value in Diagnostic Imaging
  - Dr. Martin Reed, Children’s Hospital, Winnipeg

- Reducing Imaging Tests for Low Back Pain: Can Patients Choose Wisely?
  - Dr. Nick Bansback, University of British Columbia

- The Canadian Medical Imaging Inventory: Past, Present, and Future
  - Alison Sinclair, CADTH

**Concurrent Session B4 — Oral Presentations**

**Room 201**

**PHARMACEUTICAL POLICY**

- Impact of Reduction of Generic Drug Prices Policy on Adherence to Medication
  - Fidela Mushashi, University of British Columbia

- Potential Savings From Biosimilars in Canada
  - Gary Warwick, Patented Medicine Prices Review Board

- Mergers and Acquisitions and Generics: The Impacts of This Forgotten Factor on Pricing and Shortages
  - Prof. Marc-André Gagnon, University of Ottawa Centre for Health Law, Policy and Ethics

- National Regional Health Authority Formulary Collaborative
  - Jeremy Slobodan, Alberta Health Services

**Concurrent Session B5 — Oral Presentations**

**Room 203**

**HTA METHODS**

- Harmonization of Health Technology Assessment Methods: The Pan-Canadian Experience
  - Nancy Sikich, Health Quality Ontario

- A Canadian Population Grouping Methodology - Profiling Health Utilization Across Sectors
  - Yvonne Rosehart, Canadian Institute for Health Information

- A Collaborative Approach to Assessing the Potential Value of Innovative Technologies
  - Geneviève Plamondon, Institut national d’excellence en santé et services sociaux (INESSS)

- An Efficient Solution and Implementation of the Decision Tree Problem
  - Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1330 – 1445</td>
<td><strong>Concurrent Session B6 — Oral Presentations</strong></td>
<td>Room 202</td>
</tr>
<tr>
<td></td>
<td>REAL-WORLD EVIDENCE: PHARMACEUTICALS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Alzheimer's Drug Therapy Initiative (ADTI): Drug Coverage With Evidence Development in British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Elaine Chong, British Columbia Ministry of Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pattern and Policy Reflections on a 12-Year Utilization Review of Insulin and Blood Glucose Test Strip Use in Manitoba</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Jamie Falk, University of Manitoba</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Keeping it Real: Utilization of Real-World Data Sources to Generate Real-World Evidence for Better Evidence-Based Decision-Making</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Tarry Ahuja, Eli Lilly Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Modelling the Cost-Effectiveness of Rituximab Use Compared With Tumour Necrosis Factor Inhibitors (Anti-TNF) Drugs as a Second-Line Therapy in Patients With Rheumatoid Arthritis in Quebec, Canada Using RHUMADATA Registry Data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Elena Lopatina, University of Calgary</td>
<td></td>
</tr>
<tr>
<td>1445 – 1515</td>
<td>Refreshment Break</td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Parliament Foyer 1</td>
</tr>
<tr>
<td>1515 – 1630</td>
<td><strong>Concurrent Session C1 — Panel Discussion</strong></td>
<td>Room 210</td>
</tr>
<tr>
<td></td>
<td>Canada’s Multi-Stakeholder Approach to Drug Shortages</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Elaine Chong, British Columbia Ministry of Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Michael Carter, Health Canada</td>
<td></td>
</tr>
<tr>
<td>1515 – 1630</td>
<td><strong>Concurrent Session C2 — Panel Discussion</strong></td>
<td>Room 209</td>
</tr>
<tr>
<td></td>
<td>Reimbursement Perspectives on Precision Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ferg Mills, Innomar Consulting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Olaf Koester, OHWK Business Management Advisory</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. David Shum, Roche Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Natasha Leighl, Princess Margaret Cancer Centre</td>
<td></td>
</tr>
<tr>
<td>1515 – 1630</td>
<td><strong>Concurrent Session C3 — Panel Discussion</strong></td>
<td>Room 201</td>
</tr>
<tr>
<td></td>
<td>How Do We Use Health Technology Assessment and Real-World Evidence to Implement “Reassessments” Effectively?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Christina Farup, Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Tammy Clifford, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Jeffrey Hoch, University of California</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chad Mitchell, Alberta Health Services</td>
<td></td>
</tr>
</tbody>
</table>
### MONDAY, APRIL 24, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Room</th>
</tr>
</thead>
</table>
| 1515–1630 | **Concurrent Session C4 — Panel Discussion**  
Call for Patient Input... Again  
- Sarah Berglas, CADTH  
- David Wells, Health Quality Ontario  
- Zal Press, Patient Commando Productions  
- Michael Houlahan, Sand Pile Inc.  
- Pujita Vaidya, MPH, U.S. Food and Drug Administration  
- Laurie Proulx, Canadian Arthritis Patient Alliance | 203    |
|        | **Concurrent Session C5 — Panel Discussion**  
Getting Past PowerPoint Slides and Putting Real-World Evidence Into Action  
- Jessica Arias, Cancer Care Ontario  
- Jaclyn Beca, Cancer Care Ontario  
- Angie Wong, Ontario Ministry of Health and Long-Term Care  
- Dr. Kelvin Chan, Sunnybrook Health Sciences Centre Odette Cancer Centre | 204    |
|        | **Concurrent Session C6 — Panel Discussion**  
INESSS: Improving the Value of Healthcare by Combining Knowledge-based Evidence With Real World Experience  
- Dr. Luc Boileau, INESSS  
- Dr. Catherine Truchon, INESSS  
- Laurie Lambert, INESSS  
- Dr. Melanie Tardif, INESSS | 212    |
|        | **Concurrent Session C7 — Panel Discussion**  
CADTH Health Economics Guidelines: What’s New?  
- Karen Lee, CADTH  
- Dr. Elizabeth McCarron, CADTH  
- Prof. Stirling Bryan, School of Population and Public Health, University of British Columbia  
- Prof. Doug Coyle, University of Ottawa  
- Dr. Murray Krahn, Toronto Health Economics and Technology Assessment (THETA) Collaborative  
- Prof. Christopher McCabe, University of Alberta | 202    |
|        | **Concurrent Session C8 — Panel Discussion**  
Incorporating Indigenous Perspectives into Health Technology Management  
- Valerie Gideon, ADM, First Nations and Inuit Health Branch, Health Canada  
- Dr. Marcia Anderson, University of Manitoba  
- Kathy Perrin, Government of Nunavut | 211    |
| 1800–2200 | **Social Event: A Night at the Museum**  
In keeping with Canada’s 150th anniversary, the Canadian Museum of History is the centrepiece for this evening of discovery, Canadian-inspired food, and upbeat entertainment. Special presentation by Dr. Danielle Martin, author of Better Now: Six Big Ideas to Improve Health Care for All Canadians. | Grand Hall |
Support at every step of the way of drug development...

Evidence generation
- Evidence review & synthesis
  - Systematic literature review
  - Targeted desk research
  - Network Meta-Analysis
  - Qualitative synthesis
  - Medical writing
- Economic modelling
  - Real-world evidence
  - Prospective/retrospective studies
  - Conjoint analysis
  - Clinical trial analyses
  - Biostatistics
  - Delphi panels
  - Advisory boards
  - Focus groups
  - Consensus statements
- Regional Market Access & Value Communication
  - HTA submissions and formal communication with health authorities
  - Customer facing and Value communication tools
  - Interactive value dossiers
  - Conference presentations and Workshops, Trainings

Evidence review & synthesis
- Systematic literature review
- Targeted desk research
- Network Meta-Analysis
- Qualitative synthesis
- Medical writing

To be presented at the symposium:
- Feedback on economic reviews by the Pan-Canadian Oncology Drug Review (pCODR) Expert Committee: Update
- Who funds first? Analysis of time from Pan-Canadian Oncology Drug Review Expert Committee (pERC) recommendation to provincial formulary listing

...through innovation and robustness

http://hema.amaris.com/

The Health Charities Coalition of Canada is a member based organization comprised of national health charities. Learn more about how health charities are strengthening the voice of Canadians, patients and caregivers and working with others to bring about enhanced health policy and increased investment in health research.

Email: info@healthcharities.ca
Website: www.healthcharities.ca
### Tuesday, April 25, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 1700</td>
<td>Registration Desk Open</td>
<td></td>
<td>LVL 2 Rideau Canal Atrium</td>
</tr>
<tr>
<td>0700 – 0800</td>
<td>Breakfast</td>
<td></td>
<td>LVL 2 Rideau Canal Atrium and LVL 3 Canada Hall 1</td>
</tr>
</tbody>
</table>
| 0730 - 0830 | **Breakfast Session 1**                      | Room 201 | The Health Technology Expert Review Panel – Developing Recommendations on the Optimal Use of Medical Devices, Diagnostic Tests, and Procedures  
• Dr. Stirling Bryan, School of Population and Public Health, University of British Columbia  
• Dr. Hilary Jaeger, Former Surgeon General, Canadian Armed Forces (retired)  
• Dr. Jeremy Petch, Li Ka Shing Knowledge Institute  
• Chris Kamel, CADTH |
|             | **Breakfast Session 2**                      | Room 202 | What I Know Now That I Wish I Had Known Then: A Rapid Mentorship Session on How to Succeed in Health Technology Assessment  
• Shannon Kelly, University of Ottawa  
• Dr. Doug Coyle, University of Ottawa  
• Michelle Mujoomdar, CADTH  
• Dr. George Wells, University of Ottawa  
• Dr Sharon Straus, St. Michael’s Hospital/Li Ka Shing Knowledge Institute/University of Toronto |
|             | **Breakfast Session 3**                      | Room 203 | Why Did I Do That? A Systemic Evaluation of Factors Contributing to Over-Investigations and Over-Diagnosis  
• Dr. Malvinder Parmar, Northern Ontario School of Medicine |
|             | **Breakfast Session 4**                      | Room 204 | Making Treatment Decisions in the Real World Isn’t Just Spinning the Wheel of Fortune  
• Linda Wilhelm, Canadian Arthritis Patient Alliance  
• Donna Thomson, The Caregiver Network  
• Alan Birch, North York General Hospital  
• Louise Binder, Canadian Cancer Survivor Network |
|             | **Breakfast Session 5**                      | Room 209 | Health Equity in Guideline Development: New GRADE Guidance  
• Dr. Vivian Welch, Director, Methods Centre-Bruxere Research Institute, Assistant Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa |
|             | **Breakfast Session 6**                      | Room 210 | Responding to the Opioid Crisis in Canada  
• Dr. Janice Mann, CADTH |
|             | **Breakfast Session 7**                      | Room 211 | The Public – How Can It Contribute to an Understanding of and Decisions About the Value of a New Health Technology?  
• Prof. Devidas Menon, University of Alberta  
• Dr. Jackie Street, University of Adelaide  
• Dr. Tania Stafinski, University of Alberta  
• Ken Bond, CADTH |
|             | **Breakfast Session 8**                      | Room 212 | An Inside Look at the Early History of the CADTH Common Drug Review  
• Barb Shea, former Vice-President, Common Drug Review, CADTH  
• Elaine MacPhail, former Director, Common Drug Review, CADTH |
TUESDAY, APRIL 25, 2017

0845 – 1000
PLENARY SESSION 2
Meaningful Stakeholder Engagement
The panel will explore how and when different stakeholders want to be engaged, and how effective engagement can help achieve high value for the health care system.
- Dr. Stuart Peacock, Leslie Diamond Chair in Cancer Survivorship at Simon Fraser University and Co-Director of the Canadian Centre for Applied Research in Cancer Control
- MJ DeCoteau, Founder and Executive Director, Rethink Breast Cancer
- Pamela Fralick, President, Innovative Medicines Canada
- Marcia Anderson, MD MPH FRCP, Head, Section of First Nations, Métis and Inuit Health, Max Rady College of Medicine, University of Manitoba
- Janet Knox, President and CEO, Nova Scotia Health Authority

1000 – 1030
Refreshment Break

1030 – 1145
Concurrent Session D1 — Oral Presentations
Room 210
ETHICAL, LEGAL, AND SOCIAL ISSUES IN HEALTH TECHNOLOGY ASSESSMENT
A Systematic Review of Ethical Issues in the Health Technology Assessment of Ovarian Stimulation and Ovulation Induction: Convergence and Disjuncture
- Shawn Winsor, McMaster University
Medical Assistance in Dying (MAiD): A Scoping Review of International Literature
- Grace Suva, Registered Nurses’ Association of Ontario
From Principles of Screening to Principles of Diagnostic Technology: A Dynamic Interpretation of Wilson and Jungner’s Principles
- Prof. Lynette Reid, Dalhousie University
Prohibition Infringing on Charter Rights: Examining the Logic Defending Commercial Reproductive Labour and Medical Assistance in Dying
- Kathryn Morrison, University of Waterloo

Concurrent Session D2 — Oral Presentations
Room 201
IMPLEMENTATION
Reviewing Implementation Issues in Dialysis: Challenges and Opportunities
- Eftyhia Helis, CADTH
A Systems Approach in the Management of Health Technology: Evaluating Value Through Real-World Evidence
- Dr. Hameed Khan, Alberta Innovates
- Bob Rauscher, MEDEC
Using Real-World Evidence to Support Increased Client Access to Health Care via Telehealth
- Karen Tulk, Western Health, Newfoundland and Labrador
Making Informed Technology Decisions: How to Move From “Adoption in Principle” to “Adoption in Practice”
- Thomas Mullie, Alberta Health Services

Concurrent Session D3 — Oral Presentations
Room 204
ONCOLOGY
Putting Policy Into Practice: Learning From Real-World Implications
- Charlotte Hoskin, Cancer Care Ontario
Generating Population-Based Real-World Evidence in Oncology Drugs
- Dr. Kelvin Chan, Sunnybrook Health Sciences Centre Odette Cancer Centre
Feedback on Economic Models From the CADTH pan-Canadian Oncology Drug Review (pCODR)
Expert Committee: An Update
- Rebecca Hancock-Howard, Amaris
### TUESDAY, APRIL 25, 2017

#### Concurrent Session D4 — Oral Presentations  
**Room 209**  
**SURGICAL INTERVENTIONS**
- A Real-Life Evaluation of Implementation Facilitators, Barriers, and Context for the Successful Introduction of a Novel Surgical Procedure: The Direct Anterior Approach for Total Hip Arthroplasty  
  • Dr. Paule Poulin, Alberta Health Services
- The Long-Term Cost-Effectiveness of Bariatric Surgery for the Treatment of Severe Obesity: A Cost-Utility Analysis From a Societal Perspective  
  • Dr. Erica Lester, University of Alberta
- Value in Surgical Quality Improvement Programs: A Real-World Example From The Ottawa Hospital  
  • Sasha van Katwyk, The Ottawa Hospital Research Institute

#### Concurrent Session D5 — Oral Presentations  
**Room 203**  
**HEPATITIS C**
- New Oral Hepatitis C Medications: Are They Living up to Their Expectations in a Real-World Setting?  
  • Kevin Wilson, Saskatchewan Ministry of Health
- Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada  
  • Dr. William W.L. Wong, University of Waterloo
- Health Utilities in Chronic Hepatitis C Patients With Decompensated Cirrhosis or Hepatocellular Carcinoma  
  • Yasmin Saeed, University of Toronto
- Hepatitis C Virus Treatment Prioritization Improves Population Health Outcomes  
  • Prof. Lauren Cipriano, Western University

#### Concurrent Session D6 — Oral Presentations  
**Room 211**  
**OBSTRUCTIVE SLEEP APNEA**
- The Value of Stratified Economic Analysis in Informing Decision-Making: A Case Study of Interventions for Obstructive Sleep Apnea  
  • Dr. Bernice Tsoi, CADTH
- Economic Evaluation of a Portable, Home-Testing Device (BresoDx) for Obstructive Sleep Apnea  
  • Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute
- Diagnostic Accuracy of Level IV Portable Sleep Monitors Versus Polysomnography for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis  
  • Dr. Lusine Abrahamyan, Toronto Health Economics and Technology Assessment (THETA) Collaborative and University of Toronto
- SIESTA Home Sleep Study With BresoDx Portable Monitor for the Diagnosis of Obstructive Sleep Apnea: A Pragmatic Randomized Controlled Trial  
  • Dr. Valerie Rac, Toronto Health Economics and Technology Assessment (THETA) Collaborative and University of Toronto
**TUESDAY, APRIL 25, 2017**

**1030 – 1145**

**Concurrent Session D7 — Oral Presentations**

**Room 202**

**PHARMACY**

Costs and Savings Associated With the Pharmacists Prescribing for Minor Ailments Program in Saskatchewan
- Ellen Rafferty, University of Saskatchewan
- Dr. Marwa Farag, University of Saskatchewan
- Mohsen Yaghoubi, University of Saskatchewan

Economic Analysis of Pharmacist-Administered Influenza Immunizations in Ontario
- Prof. Daria O’Reilly, McMaster University

Screening for Atrial Fibrillation in Canadian Pharmacies Is a Cost-Effective Strategy
- Dr. Jean-Eric Tarride, McMaster University

Do Clinicians Back the Backgrounders? Perceptions and Acceptance of Backgrounders by Pharmacists
- Jeremy Slobodan, Alberta Health Services

**Concurrent Session D8 — Oral Presentations**

**Room 212**

**MEANINGFUL STAKEHOLDER ENGAGEMENT**

The Matters Approach to Clinical Engagement
- Lisa Pyke, CADTH
- Jennifer Boswell, Health PEI

Making HTA Relevant in the Innovation Policy Landscape
- Mark Campbell, National Institute for Health and Care Excellence (NICE)

Evaluation of Patient and Public Involvement Initiatives in Health Technology Assessment: An Environmental Scan
- Dr. Laura Weeks, CADTH

**1145 – 1315**

**AWARDS LUNCHEON**

**LVL 3 Canada Hall 1**

**1315 – 1430**

**Concurrent Session E1 — Panel Discussion**

**Room 210**

Assessing the Value of Diagnostic Innovation: A Growing Role for Health Technology Assessment?
- Dr. Fiona Miller, University of Toronto
- Dr. Tammy Clifford, CADTH
- Dr. Irfan Dhalla, Health Quality Ontario
- Dr. François Rousseau, Université Laval

**Concurrent Session E2 — Panel Discussion**

**Room 201**

Implementing Health Technology–Related Decisions: The Opportunities and Challenges in a Local Health Care Setting
- Dr. Julie Polisena, CADTH
- Dr. Eric Cohen, Sunnybrook Hospital
- Dr. Daniel James Niven, University of Calgary
- Hal Hilfi, The Ottawa Hospital
- Dr. Don Juzwishin, Alberta Health Services.

**Concurrent Session E3 — Panel Discussion**

**Room 209**

Use of the Resident Assessment Instrument – Minimum Data Set (RAI-MDS 2.0) and interRAI Long-Term Care Facilities Assessment Systems to Inform Policy and Improve Practice and Health Outcomes in Long-Term Care Residents
- Selma Didic, Canadian Foundation for Healthcare Improvement
- Dr. Kaye Phillips, Canadian Foundation for Healthcare Improvement
- Geri St. Louis, Canadian Institute for Health Information
- Julie Weir, New Brunswick Association of Nursing Homes
**Tuesday, April 25, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>1315 – 1430</td>
<td><strong>Concurrent Session E4 — Panel Discussion</strong></td>
<td>203</td>
</tr>
<tr>
<td></td>
<td>Fair Pricing of Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Eric Lun, British Columbia Ministry of Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tanya Potashnik, Patented Medicines Price Review Board</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session E5 — Panel Discussion</strong></td>
<td>204</td>
</tr>
<tr>
<td></td>
<td>To Model or not to Model, What Is the Question?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prof. Jeffrey Hoch, University of California</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Chris Cameron, Cornerstone Research Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jack Ishak, Evidera</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jaclyn Beca, Cancer Care Ontario</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Frederico Felizzi, Hoffmann-La Roche</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session E6 — Panel Discussion</strong></td>
<td>212</td>
</tr>
<tr>
<td></td>
<td>Creating Criteria Using Patient Experience for High-Cost Rare-Use Drugs With Limited Evidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jeremy Slobodan, Alberta Health Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. James Silvius, Alberta Health Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Irvin Mayers, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Concurrent Session E7 — Panel Discussion</strong></td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>New Innovations in Combining Clinical Data and Real World Evidence to Understand the Long-term Impact of Therapies: The Future is Here</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Brad Millson, QuintilesIMS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Charles Victor, Institute for Clinical Evaluative Sciences</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Marie-Claude Laliberté, Abbvie Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tara Gomes, St. Michael’s Hospital</td>
<td></td>
</tr>
<tr>
<td>1430 – 1500</td>
<td><strong>Refreshment Break</strong></td>
<td></td>
</tr>
<tr>
<td>1500 – 1615</td>
<td><strong>Closing Plenary</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aligning Regulation and Reimbursement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>An expert panel will discuss the issues, challenges, and opportunities associated with aligning regulatory and reimbursement processes for health technologies more closely so that value is considered earlier in the overall process.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Michele Evans, Assistant Deputy Minister, Pharmaceutical &amp; Supplementary Health Benefits Division, Alberta Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• John Helou, President, Pfizer Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Robyn Lim, PhD, Senior Science Advisor, Health Products and Food Branch, Health Canada</td>
<td></td>
</tr>
<tr>
<td>1615 – 1630</td>
<td><strong>Official Closing</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Brian O’Rourke, President and CEO, CADTH</td>
<td></td>
</tr>
</tbody>
</table>
2017 CADTH SYMPOSIUM APP
Search for “CADTH” in the app store to download the app to your mobile device or download directly at: http://bv1ytw.m.attendify.com/
COMMITTEES

CADTH thanks the members of its Symposium committees for their hard work and tremendous effort.

Program Advisory Committee
Linda Wilhelm
Dr. Allan Grill
Lesley Soril
Bonnie Kam
Maximiliano (Max) Iglesias
Andrea Tricco
Mike Paulden
Tonya Somerton
Scott Gavura
Marc Rhainds
Ken Bond
Trevor Richter
Karen Lee
Amy Sood
Laura Weeks
Randy Allan
Janet Crain
Peter Chinneck
Lesley Dunfield
Alexandra Chambers
Carlos Rojas-Fernandez
Gord Blackhouse
Paula Neves
Peter Dyrda
Dr. Olga Gajic-Veljanoski
Danica Wasney
François-Xavier Houde
Rohit Khanna
Heather Scarlett-Ferguson
Sandra Milev
Jackie Poncelet
Kukuh Noertjojo
Mo Amin
Angela Rocchi
Mubashir Arain
Lusine Abrahamyan
Julie Polisena
Caroline C. Jeffery
Cody Hotel
Kimberly Robinson
Shweta Pai
Renata Osika
Dr. Alexei Botchkarev
Darren Pasay
Sharon Marsh
Judith Fisher
Janice Mann
Myra Wang
Elena Lungu
Eva Tsakonas
Dr. David Guerrero
Neil Corner
Sonja Sawh
Yeeshah Poon
Andriy Moshyk
Dale Quest
Janet Martin
Kim Yoong
Laura Oliveira
Paule Poulin
Shakuntala Soden
Brendan McIntosh
Liz Keay
Brent Korte
Lisa Pyke
Micheal Guirguis
Seija Kromm
Ferg Mills
Fang Zhu
Stacy Kozak
James Murtagh
Leigh-Ann Topfer
Wanrudee Isaranuwatchai
Rohini Naipaul
David GT Whitehurst
Marg Hux
Bobby Currie
Shannon Kelly
Marc Pelletier
Karen MacCurdy Thompson
Man Wah Yeung
Mathieu Talbot
Marie-Pierre Gagnon
Lisa Milgram
Dr. Patricia Chan
Melodi Kosaner Kliess
Noelle O’Neill
Jennifer LaRosa
Janet Crain
Isabelle Chabot
Vicki Foley
Rebecca Mercer
René Lavallée
Simon Yunger
Dr. Anne Holbrook
Eon Ting
Stacey Hickson
Stephen Congly
Tara Schuller
Sumit Chhabra
Carmen Moga
Cynthia Haskins
Mitchell Levine
Teo Quay
Bernice Tsoi
Jocelyn Chisamore
Joanne Kim
Jesse Elliott
Kednapa Thavorn
Avtar Lal
Maureen Smith
Farhan Abdul Rauf
Laurie Proulx
Jennifer Pereira
Iwona Bielska
Tara Bond
Stephanie Smith
Valerie McDonald
Lisa Masucci
Lauren Bresee
Carolyn Trumper
Marina von Pinoci
Mary-Ellen Hogan
Tara Gones
Devidas Menon
Safia Khalfan
Tamara Rader
Doug Vincent
Kristen Moulton
Christine Malmberg
Adina Gottardi
Ruolz Ariste
Shan Satoglu
Matthew Hodge
El Kebir Ghandour

CADTH Recognition Awards Selection Committee
Dr. Yvonne Bombard
Dr. Nick Bansback
Dr. Fiona Clement
Dr. Tom Noseworthy
Dr. Tammy Clifford
Dr. Brian O’Rourke
Dr. Terrence Sullivan

Symposium Moderator
Peter Chinneck

CADTH Events Team
Shannon Kerr
Josee Nugent
The Canadian Association for Population Therapeutics/
Association Canadienne pour la Thérapeutiques des Populations
Presents:

Patient Engagement and Outcomes: 
Taking it to the Next Level

October 23rd – 24th, 2017
MaRS Discovery District
Toronto, Ontario

Join us as we discuss:
- Aligning health technology assessments with the patient voice
- Patient-centred health policy developments
- Methods for engaging patients in therapeutic and outcomes research
... and much more!

For more information, please visit:
www.capt-actp.com
2018 is going to be a big year for HTA in Canada

2018 CADTH Symposium
April 15 to 17, 2018
cadth.ca/symposium2018

Halifax, NS

HTAi 2018 Annual Meeting
June 1 to 5, 2018
htai.org

Two world class Health Technology Assessment conferences — one on the west coast, one on the east coast.